Ocella, the generic equivalence of Yaz or Yasmin contains ethinyl estradiol and progestin drospirenone (DRSP). Drospirenone is already well-known for increasing the risk of hyperkalemia. In addition the Food and Drug Administration has also associated DRSP oral contraceptives with adverse reactions including: blood clots, deep vein thrombosis (DVT), pulmonary emoblism (PE), stroke, cerebrovasular accidents, heart attack, myocardial infraction, gallbladder disease, gallbladder removal (cholecstectomy), kidney failure or renal failures, pancreatitis and even death.

What makes Yaz, Yasmin and Ocella so different from other birth control pills?

All brith control options are associated with health risks, especially for females over 35-years of age who smoke cigarettes. However, the oral contraceptive pill Yaz, Yasmin and Ocella have the distinction of being associated with a potentially higher risk of blood clots. Serious side effects like stroke, heart attack, pulmonary embolism, as well as deep vein thrombosis are all risk factors of blood clots.

Bayer HealthCare Pharmaceuticals, Inc., the manufacturer of Yaz, Yasmin and Ocella has received numerous warning letters from the U.S. Food and Drug Administration concerning their misleading advertisement and container testing at their plants.

In 2009, Bayer HealthCare Pharmaceutials, Inc. was required by the Food and Drug Administration warning letter to sponsor a $20 million advertising campaign to correct previous Yaz advertisement that overstated the benefits and understated the risks of brith control pill.

If you or your loved one has suffered serious side effects or injury from using the birth control pill Yaz/Yasmin, contact us immediately for a free online or telephone consultation.